More Stories

Informist, Friday, Jul. 31, 2026

 

MUMBAI – The Nifty Pharma index is expected to outperform headline indices on its way up next week. The index ended higher this week, supported by a sharp rise in shares of domestic-focused companies, which are likely to continue to do well. Additionally, with the war in West Asia once again putting pressure on interest rate- and crude-sensitive stocks, a sectoral rotation in favour of these companies is likely.

 

Traders will also closely watch the June quarter earnings announcements of GlaxoSmithKline Pharmaceuticals, Aurobindo Pharma, Lupin, and Biocon, among other pharmaceutical companies next week. Domestic sales of drugmakers are expected to remain strong, sparking interest in shares of India-focused companies. However, shares of US-focused companies may come under pressure as their revenues continue to be dragged down by sharply lower generic Revlimid sales.

 

Consequently, Sun Pharmaceutical Industries, which Friday reported a large fall in US sales, could see some more selling pressure. The pharma major reported solid growth in domestic sales and its management said the company is now the second-biggest generic semaglutide player in the Indian pharmaceutical market, which could allay investors' worry over the growth prospects of the company. Analysts are keenly monitoring commentary from companies which have a sizeable presence in the US as they want to understand which drug or segment could be the next lever of growth in the absence of generic Revlimid sales. The management of Sun Pharma is convinced that this growth will come from its innovative drug portfolio which includes drugs such as Ilumya, Cequa, and Leqselvi.

 

Analysts said the inelastic demand for pharmaceutical products will continue to drive volumes amid the war in West Asia. With the war between the US and Iran escalating rapidly and spreading to other countries, crude oil prices are likely to rise more, something that has prompted sectoral rotation towards pharma stocks in the past. Iran Friday said transit through the Strait of Hormuz is impossible because of the continued aggressive actions of US forces in the region, several media reports said, citing the country's Fars news agency. "Once stability and calm are restored, all requests will be reviewed based on their order and scheduling, and permits will be issued gradually," according to media reports quoting Iran's Persian Gulf Strait Authority.

 

This week, the Nifty Pharma index ended nearly 4% higher at 26534.80 points. Laurus Labs, Divi's Laboratories, and Piramal Pharma ended 7-13% higher this week. Meanwhile, IPCA Laboratories, Mankind Pharma, and Biocon fell 1–2%.

 

The Nifty Pharma index is gradually moving north with higher-highs and higher-lows while holding strong above its long-term as well as short-term moving averages, Vipin Kumar, assistant vice-president of research at Globe Capital Market, said. "Going ahead, we uphold our bullish view on this space and suggest traders to continue with buy-on-dips trading approach," the analyst said. He expects the index to find support at 26000–25800 points and face resistance at 26800–27200 points.

 

TOP HEADLINES

* Earnings Review: Sun Pharma Q1 earnings misses estimates on Revlimid drag
* Strides Pharma Apr-Jun consol PAT rises 58% YoY to INR 1.57 billion
* Lupin launches Sugammadex injection in US post FDA approval
* Analyst Concall: Torrent Pharma eyes swift recovery in semaglutide mkt share
* Analyst Concall: Mankind Pharma sees West Asia war weighing on gross margin
* Earnings Review: Aarti Industries Q1 PAT up over threefold, beats view
* Earnings Review: High sales boost Torrent Pharma's PAT in June quarter
* Alivus Life Sciences Apr-Jun PAT rises 32% YoY to INR 1.6 billion
* Analyst Concall: Ajanta Pharma sticks to guidance of INR 4 bln capex in FY27
* Earnings Review: Mankind Pharma PAT up 30% YoY on slow rise in costs
* Earnings Review: Ajanta Pharma beats Street on strong US, India sales
* Analyst Concall: Piramal Pharma sees growth in intl ops lifting FY27 margin
* US FDA issues three observations to Dr Reddy's Andhra Pradesh unit
* Sun Pharma gets Brazil health authority nod to supply semaglutide injection
* Earnings Review: Piramal Pharma Q1 loss narrows; beats Street estimates
* Earnings Review: Syngene Q1 slips to loss as revenue falls 17%
* Delhi HC refuses to stay administration of Human Papillomavirus vaccine
* Eris Life Apr-Jun consol PAT rises 20.7% YoY to INR 1.42 billion
* Gland Pharma gets US FDA OK for sugammadex injection, launches via partner
* Biocon arm gets approval from Health Canada for Yesintek autoinjector pen
* Glenmark Pharma arm launches Sugammadex injection in US market
* Earnings Review: Pfizer Q1 PAT up 8% on year, beats Street estimate
* Alembic Pharma gets US FDA nod for Prucalopride tablets in 1, 2 mg strength
* Cipla gets US FDA nod for generic asthma drug Advair Diskus in 3 strengths
* Sun Pharma partner resubmits skin cancer pdt Nidlegy to European regulator
* Pfizer CFO Amit Agarwal resigns with effect from Oct 8
* Dr Reddy's says Thailand drug regulator approves gonorrhoea drug zoliflodacin
* Galderma launches regenerative aesthetic injectable Sculptra in India
* SC allows Intas Pharma to sell cancer drug in Sun Pharma arm trademark case
* Earnings Outlook: Custom synthesis ops to lift Divi's Labs Q1 earnings
* Zydus Life suspends ops at Ahmedabad units as preventive measure
* Piramal Pharma shuts ops at Sanad temporarily amid floods, waterlogging
* Aurobindo Pharma in pact with Merck Sharp to supply generic alimatravir drug
* Analyst Concall: Laurus Labs ups FY27 capex to INR 20 bln to fund expansion
* Onesource Specialty posts INR-250-mln consol PAT Apr-Jun vs loss year ago
* Earnings Review: Laurus Labs Q1 consol PAT surges 126%, beats street views

 

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	27800.00	(-)0.70	28153.30	27253.30
Alkem Laboratories	5751.50	2.10	5871.20	5675.20
Aurobindo Pharma	1580.20	3.20	1600.70	1555.90
Biocon	425.70	(-)1.80	431.00	420.30
Cipla	1473.20	4.40	1487.90	1454.90
Divi's Laboratories	8056.00	11.10	8225.00	7786.00
Dr Reddy's Laboratories	1148.10	(-)0.30	1160.60	1135.40
Gland Pharma	2502.90	5.20	2548.80	2477.00
GlaxoSmithKline Pharmaceuticals	2655.40	5.60	2747.30	2518.70
Glenmark Pharmaceuticals	2233.90	1.90	2282.20	2182.80
Granules India	824.65	(-)1.10	849.20	810.20
Ipca Laboratories	1747.80	(-)0.90	1795.70	1717.10
Laurus Labs	1816.20	13.40	1850.90	1767.70
Lupin	2415.00	1.90	2449.00	2387.00
Natco Pharma	917.00	(-)0.50	944.50	899.20
Pfizer	4823.90	4.30	4885.40	4749.20
Sanofi India	3318.00	(-)2.10	3444.70	3226.70
Sun Pharmaceutical Industries	1990.50	2.50	2082.50	1919.30
Torrent Pharmaceuticals	5122.80	3.30	5298.90	4806.30
Zydus Lifesciences	1126.80	1.60	1142.90	1109.70
Index	Levels
Nifty Pharma	26534.80	3.90	26881.20	26241.50
Nifty 50	24383.60	2.60	24500.60	24241.20
S&P Bse Sensex	78094.64	2.70	78521.30	77596.60

 

End

 

Reported by Eshitva Prakash

Edited by Shubhayan Bhattacharya

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.